MEDARTIS: 1H in-line, but murkier outlook and guidance cut for remainder ‘22 | BUY | CHF175
MEDARTIS - BUY | CHF1751H in-line, but murkier outlook and guidance cut for remainder ‘22
1H headline broadly in line, but some pressure on ‘22e 2H forecasts in our view
Re-iterate Buy, CHF 175 TP as long term Upper and Lower extremities thesis is intact
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.